#Israel #Tel Aviv #retinal diseases #Everads Therapy #Suprachoroidal Injector

Everads Therapy Breaks New Ground in Ophthalmology

Everads Therapy, a pioneering company in the field of ophthalmology, has recently shared significant findings from its first-in-human clinical trial regarding its innovative suprachoroidal delivery technology. This groundbreaking approach is targeted at advancing the treatment methods for retinal diseases, with a special focus on conditions such as diabetic macular edema. The publication highlights not only the safety and tolerability of the device but also reflects a remarkable performance record.

In its peer-reviewed study published in Ophthalmology Science, a prestigious journal of the American Academy of Ophthalmology, Everads reported that the clinical trial (NCT06314217) demonstrated both procedural feasibility and ease of use. Conducted in an office-based setting, the trial assesses the safety and effectiveness of the Everads Injector, which was utilized to administer a suspension of triamcinolone acetonide directly into the suprachoroidal space of the eye. The results were promising, showcasing a favorable safety profile along with efficient drug distribution.

Dr. Yoreh Barak, MD, who serves as the Head of Retina at Rambam Medical Center and Principal Investigator of the study, stated, "As we gain further insight into the suprachoroidal space as a viable route for treating retinal diseases, the demand for safe and dependable delivery techniques continues to grow. The Everads Injector has exhibited encouraging safety, tolerability, and operational simplicity. Its capability to allow controlled access and offer targeted drug distribution differentiates it from traditional methods."

The innovation doesn’t stop there. Moshe Weinstein, Executive Chairman of Everads, expressed his enthusiasm for the publication, emphasizing that this milestone not only validates the potential of their platform but also could significantly broaden the utilization of suprachoroidal delivery across various retinal therapies. "We foresee extensive applications for this technology, especially for treatments requiring rapid, targeted drug distribution," Weinstein added.

At the heart of the Everads Injector's technology is a proprietary non-sharp tissue separator designed for controlled tissue separation. This unique mechanism allows for simultaneous tangential delivery towards the eye's posterior segment, facilitating a targeted distribution approach to crucial areas such as the posterior pole and macular region. This technological advancement marks a significant leap forward in non-surgical, office-based procedures for eye health.

In addition to the published findings, Everads will present new insights at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting taking place in Denver, Colorado. Three presentations will explore the use of thermal imaging to monitor the drug distribution patterns achieved with their injector, providing further validation for this promising delivery technique.

Presentation details include:
1. Real-time infrared ocular thermography for confirming suprachoroidal delivery in humans | Barak, Y et al | May 3, 800–945 am | Poster #0072
2. Near-Real Surgical Specimens (NRSS) for Standardized Assessment of Suprachoroidal Drug Delivery | Almeida, D et al | May 5, 330–515 pm | Poster #0693
3. Infrared Thermal Imaging Differentiates Intravitreal from Suprachoroidal Injection Patterns in Humans | Zaher, E et al | May 5, 115–300 pm | Poster #0502

Everads Therapy is dedicated to enhancing the potential for retinal disease treatments through its novel suprachoroidal delivery platform. This innovation aims for not only safe drug distribution but also rapid, effective targeting of explicitly designed areas within the eye, shaping a brighter future for patients. Established as a spin-off from DALI Medical Devices and affiliated with the RAD Biomed accelerator, Everads continues to collaborate with leaders across various fields, making strides toward comprehensive solutions in ophthalmology.

For more information on Everads Therapy and its pioneering technology, you can visit Everads Therapy or follow their updates on LinkedIn.